Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

act is significantly reduced and, as the iron is retained within the product if it is not absorbed, it is expected this will significantly reduce the risk of unwanted side effects within the gastrointestinal tract.

The international, multicentre, randomised, double-blind and placebo controlled AEGIS 1 and AEGIS 2 studies will investigate the potential of ST10 as a twice-daily treatment of IDA in subjects with Ulcerative Colitis (UC) or Crohn's disease respectively where oral ferrous preparations have failed or cannot be used.  The studies are each enrolling 120 patients and will measure patients' change in haemoglobin concentration from baseline to week 12.  Initial results from both studies are expected to be reported in late 2012 and, if positive, will be promptly followed by filings of marketing authorisation applications in key pharmaceutical markets.  In addition, Shield is planning to initiate a Phase 3 study of ST10 for the treatment of IDA in patients with chronic kidney disease in 2012.  

Data provided by IMS suggests that the iron market was worth $2.4 billion in 2010, of which 55% of revenues were generated from oral iron therapies.

There are currently no curative treatments available for UC or Crohn's and so treatment options are restricted to controlling symptoms, maintaining remission and preventing relapse.  IDA in both is a chronically debilitating disorder which has a significant impact on patients' quality of life and, as a result, its treatment is an important aspect of disease management.  Characteristic symptoms of IDA include chronic fatigue, headache and subtle impairment of cognitive function.  Up to one third of subjects with UC and Crohn's suffer from recurrent anaemia, with hospitalisation required in severe cases.

About Shield Therapeutics

Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an ind
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 ... de Paris en décembre ...   SARAH   », qui compare   l ... avec le   sorafénib dans le carcinome hépatocellulaire ... d,un cancer du foie avancé   ; les ...
(Date:3/3/2015)... 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... Conference in Miami, FL on March ... A. Ramsay , Chief Financial Officer, will provide a corporate ... "Investors" section of Halozyme,s corporate website at www.halozyme.com , ... following the event. To access the live webcast, please log ...
(Date:3/3/2015)... ON , March 3, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: ... $3.7 million.  The orders are for odour control projects in ... and Asia . "Bidding activity ... , President and CEO. "After a high volume year for bidding ... into the New Year.  The recent orders reflect the organization,s renewed ...
(Date:3/3/2015)... TORONTO , March 3, 2015 /CNW/- SQI Diagnostics ... and commercializes proprietary technologies and products for advanced ... Ryer CPA, CA, CFE  to its Management team. ... the Company in its transition from a development ... financing initiatives to advance the Company,s capital market ...
Breaking Biology Technology:Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Halozyme Therapeutics To Present At The Barclays 2015 Global Healthcare Conference 2SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3
... Vical Incorporated,(Nasdaq: VICL ) presentation at the ... at 1 p.m. Eastern Daylight Time, will be ... page at http://www.vical.com ., About Vical, ... on its,patented DNA delivery technologies for the prevention ...
... - Oncentra(R) RT Viewer* Officially to Launch ... ASTRO 2008, Boston, USA, September,21-24, Nucletron, a ... release of Oncentra RT Viewer. This unique innovation,in ... review,radiotherapy plans that are generated with a wide ...
... significant partial onset seizure reduction, proven ... - Keppra XR(TM) is ... press release, regulated information:,UCB announced today that the U.S. Food ... for use as,an add-on to other antiepileptic treatments for people ...
Cached Biology Technology:Vical to Present at UBS Global Life Sciences Conference 2Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy 2Video: Keppra XR(TM) Approved in the U.S. 2Video: Keppra XR(TM) Approved in the U.S. 3Video: Keppra XR(TM) Approved in the U.S. 4
(Date:2/24/2015)... -- This report analyzes the worldwide markets for Iris Biometrics ... the US, Canada , Japan ... , Middle East , and ... provided for the period 2013 through 2020. Also, a seven-year ... analytics are derived from primary and secondary research. Company profiles ...
(Date:2/24/2015)... , Feb. 24, 2015 Research and Markets ... addition of the "Global 2D Gesture Recognition ... The analysts forecast the Global 2D ... of 32.12% over the period 2014-2019 ... non-traditional sectors is one of the major trends ...
(Date:2/19/2015)... 2015 Research and Markets ( ... "Military Electro-Optical / Infrared Systems Market by ... - Forecast to 2020" report to their ... market is expected to reach $16.35 billion by ... This report segments the military electro-optical/infrared systems ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
... Celecoxib have come under scrutiny lately due to adverse ... fly and rat models, researchers reveal another adverse effect ... this effect is independent of the COX-2 enzyme. ... on the heart rate of Drosophila, a good model ...
... His friends used to think he was eccentric, crawling ... north-central Pennsylvania, hauling dental tools and a jack hammer. ... theyve gotten over it, and are congratulating him on ... Paleontological Society, presented at the Geological Society of Americas ...
... and scientific books and journals, was acquired by ... immediately available on www.springerlink.com along with ... than 22,000 eBooks. Beginning with the subscription year ... Press journals through Springer. All issues previously available ...
Cached Biology News:Academy volunteer wins national paleontology award 2Humana Press journals now available on SpringerLink 2